APPLICATION FOR NEW COURSE

1. Submitted by College of Medicine ____________________________ Date July 31, 2006
   Department/Division offering course Molecular and Biomedical Pharmacology

2. Proposed designation and Bulletin description of this course
   a. Prefix and Number See Attached
   b. Title Molecular Drug Targets and Therapeutics
      *NOTE: If the title is longer than 24 characters (including spaces), write
      A sensible title (not exceeding 24 characters) for use on transcripts

   c. Lecture/Discussion hours per week 4
   d. Laboratory hours per week
   e. Studio hours per week
   f. Credits (Variable) 1-4
   g. Course description
      See Attached

   h. Prerequisites (if any)
      IBS 601-609 & PHA 621

   i. May be repeated to a maximum of 4
      (if applicable)

4. To be cross-listed as
   Prefix and Number
   Signature, Chairman, cross-listing department
   Effective Date January 1, 2007
   (semester and year)

6. Course to be offered
   □ Fall   ✓ Spring   □ Summer

7. Will the course be offered each year?
   (Explain if not annually)
   ✓ Yes   □ No

8. Why is this course needed?
   See Attached

9. a. By whom will the course be taught?
    The Faculty of the Dept. of Molecular & Biomedical Pharmacology/COM

   b. Are facilities for teaching the course now available?
      If not, what plans have been made for providing them?
      ✓ Yes   □ No
APPLICATION FOR NEW COURSE

10. What enrollment may be reasonably anticipated? 10-15 Students

11. Will this course serve students in the Department primarily? XXX Yes □ No
   Will it be of service to a significant number of students outside the Department?
   If so, explain. XXX Yes □ No
   See Attached

12. Will the course serve as a University Studies Program course? □ Yes XXX No
    If yes, under what Area?

13. Is this course applicable to the requirements for at least one degree or certificate at the
    University of Kentucky? XXX Yes □ No

14. Is this course part of a proposed new program? If yes, which?
    □ Yes XXX No

15. Will adding this course change the degree requirements in one or more programs?
    If yes, explain the change(s) below (NOTE – If “yes,” a program change form must also be
    submitted.) □ Yes XXX No

16. Attach a list of the major teaching objectives of the proposed course and outline and/or reference list to be used.

18. If the course is 400G or 500 level, include syllabi or course statement showing differentiation for undergraduate and graduate
    students in assignments, grading criteria, and grading scales. □ Check here if 400G-500.

19. Within the Department, who should be contacted for further information about the proposed course?
    Name  Dr. Michael T. Piascik
           mtp@uky.edu
           Phone Extension (859) 323-5107
APPLICATION FOR NEW COURSE

Signatures of Approval:

7/31/06 Michael [Signature]

Date of Approval by Department Faculty

8-8-06 C.[Signature]

Date of Approval by College Faculty

Reported by Undergraduate Council Chair

8/19/06 [Signature]

*Date of Approval by Graduate Council

Reported by HCCC Chair

*Date of Approval by Health Care Colleges Council (HCCC)

Reported by Senate Council Office

*Date of Approval by Senate Council

Reported by Senate Council Office

*Date of Approval by University Senate

*If applicable, as provided by the Rules of the University Senate

Rev 7/06
# Application form

# 2 Proposed Designation

PHA 622 section 001-Cardiovascular Pharmacology
PHA 622 section 002-Neuropharmacology
PHA 622 section 003 Chemotherapeutic Agents
PHA 622 section 004 Autocoids and Endocrine Pharmacology and Toxicology

# 3 Course description

PHA 622 is an advanced course designed to provide graduate students with state of the art information regarding drugs, drug action and targets for drug action. Emphasis will be placed on drugs that interact with the cardiovascular system (PHA 622 section 001), the central nervous system (PHA 622 section 002), chemotherapeutic agents, (PHA 622 section 003) and other important drugs classes such as nonsteroidal anti-inflammatory agents, steroid hormones, antidiabetic agents and toxicology (PHA 622 section 004). Each section is designed to be a separate one hour course. Students may take any combination of sections from one to all four sections. For each agent, emphasis will be placed on the cellular mechanisms of action, the receptors or cellular targets at which they act, therapeutic uses and potential toxicities. This information is intended to be integrated with other disciplines, including anatomy, biochemistry, physiology, psychology and molecular biology.

# 8 Why is the course needed?

PHA 622 will replace PHA 522. This change is necessary to provide the most appropriate teaching experience for all students taught by the Department of Pharmacology and is a component of a larger reorganization of Departmental teaching efforts. Currently, PHA 522 is taught together with OBI 826, Dental Pharmacology. OBI 826 is a course for third year dental students. In this less than optimal arrangement graduate and dental students are taught together. This necessarily means that drug information most appropriate for dental practitioners is presented along with information most appropriate for Ph.D. students. Therefore, to rectify this situation the Department has developed PHA 622, a course designed strictly for advanced graduate students. A second aspect of this curricular reform is the modification of OBI 826 to contain material specifically tailored for dentists. This new dental course is OBI 836. In PHA 622 the fundamental principles of drug action will be presented at a sophisticated mechanistic and cellular level. Thus the student will learn the molecular targets for relevant drugs as well as the cellular signaling pathways engaged and the resulting outputs that result in the therapeutic efficacy of these agents. Potential toxicities of drugs will also be a component of PHA 622. The course is offered in four sections. Graduate students from other Departments in the College of Medicine, especially Physiology and Toxicology or other Colleges such as Pharmacy will also find this course relevant to their training programs. Completion of all four sections of PHA 622 will offer a comprehensive exploration of drugs and drug action.
However, each section is designed to be a free standing course on a discrete classification of drugs. Offering this modular course design, allow students to take any number of the four sections as is appropriate to achieve their educational objectives.

#11

Graduate students in other departments of the College of Medicine, from the College of Medicine or from Biological Sciences will find that PHA 622 provides highly relevant information that will complement their current training programs.
Response from University Registrar’s Office Regarding Varying Credit Hours in a Course

You can build more than one section of a course, with each section having different credit hours as long as the course is approved as variable credit overall. For example PHA 622 is approved for 1 - 4 credit hours. You can build section 001 for one credit hour and it can have one sub-title that would be different from section 002 which might be for 2 credit hours and a different subtitle. You can restrict enrollment in each section as well. Section three could be for 4 credit hours or, if you chose to do so, and are offering only one section for a term it can be for anywhere from 1 to 4 credits. I hope this helps clear it up for you. If not, please let me know. Thanks!

Jacquie Hager
PHA 622
MOLECULAR DRUG TARGETS AND THERAPEUTICS

PHA 622 section 001-Cardiovascular Pharmacology
PHA 622 section 002-Neuropharmacology
PHA 622 section 003 Chemotherapeutic Agents
PHA 622 section 004 Autocoids; Endocrine Pharmacology and Toxicology

COURSE DESCRIPTION
Pharmacology is the study of the effects of drugs on biologic systems. A drug is a chemical that has the ability to interact with and cause a change in a biologic system. Drugs are used in such diverse situations as the topical application of drugs to treat acne, the therapy of hypertension, the systemic use of drugs to treat cancer or in support of organ transplantation. It is thus not surprising to realize that there are 54,000 drug products on the market containing about 2,000 active ingredients. Since 1940 over 1,000 new chemical entities have been introduced as drugs. Toxic substances and environmental pollutants are also considered drugs. Therefore, understanding how these agents affect physiologic systems is also highly relevant. PHA 622 is an advanced course designed to provide graduate students with state of the art information regarding drugs, drug action and targets for drug action. Emphasis will be placed on drugs that interact with the cardiovascular system (PHA 622 section 001), the central nervous system (PHA 622 section 002), chemotherapeutic agents, PHA 622 section 003) and other important drugs classes such as nonsteroidal anti-inflammatory agents, steroid hormones, antidiabetic agents and toxicology (PHA 622 section 004). Each section is designed to be a separate one hour course. Students may take all sections, one section, or more than one section. For each agent, emphasis will be placed on the cellular mechanisms of action, the receptors or cellular targets at which they act, therapeutic uses and potential toxicities. This information is intended to be integrated with other disciplines, including anatomy, biochemistry, physiology, psychology and molecular biology. Several new drugs are introduced into therapy each year. We will use the Blackboard website as a means to effectively communicate.

COURSE OUTCOMES:

Students shall achieve the following outcomes:

Know the key drug classes used in cardiovascular therapeutics, disorders involving the central nervous system, as chemotherapeutic agents and other relevant disease states such as asthma and diabetes.

Know the receptors at which key drugs act to produce their pharmacologic actions.

Understand the cellular mechanisms of actions of key drugs including the signaling pathways engaged by the drugs to produce their effects.

Know the targets at which drugs act to produce toxicologic outcomes as well as the cellular mechanisms by which these effects occur.

Know the therapeutic uses of key drugs and understand the rationale for their uses in treating pathophysiologic conditions.
FACULTY

Course Coordinator
Michael T. Piascik, Ph.D.,
mtp@pop.uky.edu
Office: BHSRB 150
phone: 323-5107

Teaching Faculty
Eric Blalock, PhD
emblal@uky.edu
Office: MS-323B UKMC
phone: 323-8033

Rolf Craven, PhD
rolf.craven@uky.edu
Office: 213 Combs
phone: 323-3832

Robert Hadley, PhD
rhadley@uky.edu
Office: MS-371 UKMC
phone 257-6556

David Kaetzel, PhD
dmkaetz@uky.edu
Office: MN-350 UKMC
phone 257-6558

Michael Kilgore, PhD
mwlkilg0@uky.edu
Office: MN-354 UKMC
phone: 323-1821

Susan Kraner, PhD
sdkran2@uky.edu
Office: MS-313 UKMC
phone: 323-1996

Rina Plattner, PhD
rplat2@uky.edu
Office: 209 Combs
phone: 323-4778

Nada Porter, PhD
nadap@uky.edu
Office: MS-315 UKMC
phone 257-4715

Steven Post, PhD
spost@uky.edu
Office:: CTW 509
phone: 323-4933 ext 81363

Hollie Swanson, PhD
hswan@uky.edu
Office: MS-372 UKMC
phone: 323-1463

Olivier Thibault, PhD
othibau@uky.edu
Office: MS-320 UKMC
phone: 323-4863
Class Meetings
PHA 622 will meet Mon., Tues., Thurs., and Fri. at 1 pm in MS 303.

Attendance Policy
Regular class attendance is critical to success in this course. Students are expected to arrive on time for all scheduled activities. Tardiness is an inconvenience to classmates and instructors. Four unexcused absences will be allowed during the semester before a letter grade reduction is employed.

Examinations and Grading Policy
The grade for each section of PHA 622 will be determined by an examination given at the end of the section. Questions will consist of extended matching, short answer and essay type questions. The final numeric grade will be the average of grades on all four examinations. Letter grades will be given for the following numeric scores:

- A = 100-90
- B = 89.5-80
- C = 79.5-70
- E (Fail) = Below 69.5
- I = Incomplete

The examinations will be given only on the assigned day and time. Permission from the course director is required for the student to miss an exam. Rescheduling an exam and its format are at the discretion of the Course Director. Please plan your travel so as to be present for all exams. Personal travel, will not be accepted as a reason for missing the final. Answers to examinations will be posted upon conclusion of the exam and grading. If you feel that a question was graded incorrectly, this should be communicated in writing to the instructor authoring the question. This communication must be signed to be considered. Revisions to grades must be approved by the Course Director. Decisions regarding all changes in grading must be made within two weeks of the return of the examination and will be final.

Academic Dishonesty
Hopefully, cheating and plagiarism will not be an issue in this course. In many cases, students who contemplate committing breaches of academic integrity are unaware of the seriousness with which the University views the offenses or of the potential consequences. According to University Rules, the minimum punishment for either of these offenses is an "E" in the course.

Classroom Behavior
Behavior which detracts from the educational environment will not be tolerated. Professional behavior is expected. This is defined as: treating the instructors and your fellow students in a respectful and courteous manner. Instructors and students alike are entitled to professional respect from one another regardless of the similarity or divergence of viewpoint and irrespective of age or experience. Disruptive students will be asked to leave the classroom and may receive a penalty to their final grade in the course.
<table>
<thead>
<tr>
<th>Room#</th>
<th>Day</th>
<th>Date</th>
<th>Time</th>
<th>Topic</th>
<th>Instructor</th>
</tr>
</thead>
<tbody>
<tr>
<td>MN-</td>
<td>Thr</td>
<td>01/11/07</td>
<td></td>
<td>Introduction to PHA 622 and the Autonomic Nervous System</td>
<td>Piascik/Thibault</td>
</tr>
<tr>
<td>MN-</td>
<td>Fri</td>
<td>01/12/07</td>
<td></td>
<td>The Autonomic Nervous System</td>
<td>Thibault</td>
</tr>
<tr>
<td></td>
<td>Mon</td>
<td>01/15/07</td>
<td></td>
<td>M. L. KING HOLIDAY ~ NO CLASS</td>
<td></td>
</tr>
<tr>
<td>MN-</td>
<td>Tue</td>
<td>01/16/07</td>
<td></td>
<td>Receptor Regulation and Cardiovascular Function</td>
<td>Piascik</td>
</tr>
<tr>
<td>MN-</td>
<td>Thr</td>
<td>01/18/07</td>
<td></td>
<td>Receptor Regulation and Cardiovascular Function</td>
<td>Piascik</td>
</tr>
<tr>
<td>MN-</td>
<td>Fri</td>
<td>01/19/07</td>
<td></td>
<td>Vascular Drug Targets</td>
<td>Piascik</td>
</tr>
<tr>
<td>MN-</td>
<td>Mon</td>
<td>01/22/07</td>
<td></td>
<td>Hypertension</td>
<td>Piascik</td>
</tr>
<tr>
<td>MN-</td>
<td>Tue</td>
<td>01/23/07</td>
<td></td>
<td>Hypertension</td>
<td>Piascik</td>
</tr>
<tr>
<td>MN-</td>
<td>Thr</td>
<td>01/25/07</td>
<td></td>
<td>Ischemic Heart Disease</td>
<td>Hadley</td>
</tr>
<tr>
<td>MN-</td>
<td>Fri</td>
<td>01/26/07</td>
<td></td>
<td>Heart Failure and Cardiac Hypertrophy</td>
<td>Hadley</td>
</tr>
<tr>
<td>MN-</td>
<td>Mon</td>
<td>01/29/07</td>
<td></td>
<td>Heart Failure and Cardiac Hypertrophy</td>
<td>Hadley</td>
</tr>
<tr>
<td>MN-</td>
<td>Tue</td>
<td>01/30/07</td>
<td></td>
<td>Arrhythmogenesis and Antiarrhythmic Drugs</td>
<td>Hadley</td>
</tr>
<tr>
<td>MN-</td>
<td>Thr</td>
<td>02/01/07</td>
<td></td>
<td>Arrhythmogenesis and Antiarrhythmic Drugs</td>
<td>Hadley</td>
</tr>
<tr>
<td>MN-</td>
<td>Fri</td>
<td>02/02/07</td>
<td></td>
<td>The Pathophysiology of Atherosclerosis</td>
<td>Post</td>
</tr>
<tr>
<td>MN-</td>
<td>Mon</td>
<td>02/05/07</td>
<td></td>
<td>The Pathophysiology of Atherosclerosis</td>
<td>Post</td>
</tr>
<tr>
<td>MN-</td>
<td>Tue</td>
<td>02/06/07</td>
<td></td>
<td>EXAM PHA 622 SECTION 001</td>
<td>Staff</td>
</tr>
<tr>
<td>MN-</td>
<td>Thr</td>
<td>02/08/07</td>
<td></td>
<td>PHA 622 Section 002 Neuropharmacology</td>
<td>Porter</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sedative-Hypnotics and Anti-anxiety Drugs</td>
<td></td>
</tr>
<tr>
<td>MN-</td>
<td>Fri</td>
<td>02/09/07</td>
<td></td>
<td>Sedative-Hypnotics and Anti-anxiety Drugs</td>
<td>Porter</td>
</tr>
<tr>
<td>MN-</td>
<td>Mon</td>
<td>02/12/07</td>
<td></td>
<td>Antiepileptics</td>
<td>Blalock</td>
</tr>
<tr>
<td>MN-</td>
<td>Tue</td>
<td>02/13/07</td>
<td></td>
<td>Neurodegenerative Conditions</td>
<td>Blalock</td>
</tr>
<tr>
<td>MN-</td>
<td>Thr</td>
<td>02/15/07</td>
<td></td>
<td>Mood Stabilization and Antidepressants</td>
<td>Porter</td>
</tr>
<tr>
<td>MN-</td>
<td>Fri</td>
<td>02/16/07</td>
<td></td>
<td>Opioid Analgesics</td>
<td>Blalock</td>
</tr>
<tr>
<td></td>
<td>Date</td>
<td>Course Title</td>
<td>Instructor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>-----------</td>
<td>------------------------------------------------------------------------------</td>
<td>------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MN</strong></td>
<td>Mon 02/19/07</td>
<td>Opioid Analgesics</td>
<td>Bialock</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MN</strong></td>
<td>Tue 02/20/07</td>
<td>Drugs of Abuse</td>
<td>Norris</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MN</strong></td>
<td>Thr 02/22/07</td>
<td>Drugs of Abuse</td>
<td>Norris</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MN</strong></td>
<td>Fri 02/23/07</td>
<td>Local Anesthetics</td>
<td>Hadley</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MN</strong></td>
<td>Mon 02/26/07</td>
<td>General Anesthetics</td>
<td>Hadley</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MN</strong></td>
<td>Tue 02/27/07</td>
<td>Anti-psychotics</td>
<td>Norris</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MN</strong></td>
<td>Thr 03/01/07</td>
<td>Novel Therapeutic Approaches</td>
<td>Thibault</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MN</strong></td>
<td>Fri 03/02/07</td>
<td>EXAM 2 PHA 622 SECTION 002</td>
<td>Staff</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MN</strong></td>
<td>Mon 03/05/07</td>
<td>PHA 622 Section 002 Chemotherapeutic Agents Cancer Chemotherapy</td>
<td>Craven</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MN</strong></td>
<td>Tue 03/06/07</td>
<td>Experimental Cancer Therapeutics</td>
<td>Plattiner</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MN</strong></td>
<td>Thr 03/08/07</td>
<td>Experimental Cancer Therapeutics</td>
<td>Craven</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MN</strong></td>
<td>Fri 03/09/07</td>
<td>Experimental Cancer Therapeutics</td>
<td>Kaetzel</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>SPRING BREAK MARCH 12-17, 2007</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MN</strong></td>
<td>Mon 03/19/07</td>
<td>Sex Hormones</td>
<td>Kilgore</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MN</strong></td>
<td>Tue 03/20/07</td>
<td>Nuclear Receptors</td>
<td>Kilgore</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MN</strong></td>
<td>Thr 03/22/07</td>
<td>Adrenal Steroids</td>
<td>Swanson</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MN</strong></td>
<td>Fri 03/23/07</td>
<td>Antivirals</td>
<td>Kaetzel</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MN</strong></td>
<td>Mon 03/26/07</td>
<td>Antibiotics</td>
<td>Krane</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MN</strong></td>
<td>Tue 03/27/07</td>
<td>Antibiotics</td>
<td>Krane</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MN</strong></td>
<td>Thr 03/29/07</td>
<td>Tuberculosis</td>
<td>Craven</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MN</strong></td>
<td>Fri 03/30/07</td>
<td>Antifungals</td>
<td>Kaetzel</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MN</strong></td>
<td>Mon 04/02/07</td>
<td>Antiparasitics</td>
<td>Kilgore</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MN</strong></td>
<td>Tue 04/03/07</td>
<td>Vaccine Development</td>
<td>Faculty</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MN</strong></td>
<td>Thr 04/05/07</td>
<td>EXAM 3 PHA 622 SECTION 003</td>
<td>Staff</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MN</strong></td>
<td>Fri 04/06/07</td>
<td>PHA 622 Section 003 Autocoids, Endocrine Pharmacology and Toxicology</td>
<td>Kilgore</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Non-steroidal Anti-inflammatory Agents</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MN</strong></td>
<td>Mon 04/09/07</td>
<td>Aspirin-Acetaminophen-Anti Gout</td>
<td>Kilgore</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MN</strong></td>
<td>Tue 04/10/07</td>
<td>Migraine</td>
<td>Blalock</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MN</strong></td>
<td>Thr 04/12/07</td>
<td>Immunosuppressants</td>
<td>Norris</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MN-</strong></td>
<td>Fri</td>
<td>04/13/07</td>
<td>Gastrointestinal Pharmacology</td>
<td>Craven</td>
<td></td>
</tr>
<tr>
<td><strong>MN-</strong></td>
<td>Mon</td>
<td>04/16/07</td>
<td>Pulmonary Pharmacology</td>
<td>Plattner</td>
<td></td>
</tr>
<tr>
<td><strong>MN-</strong></td>
<td>Tue</td>
<td>04/17/07</td>
<td>Pituitary/Thyroid Drugs</td>
<td>Plattner</td>
<td></td>
</tr>
<tr>
<td><strong>MN-</strong></td>
<td>Thr</td>
<td>04/19/07</td>
<td>Anti-diabetic Drugs</td>
<td>Porter</td>
<td></td>
</tr>
<tr>
<td><strong>MN-</strong></td>
<td>Fri</td>
<td>04/20/07</td>
<td>Contraceptives/Hormone Replacement</td>
<td>Porter</td>
<td></td>
</tr>
<tr>
<td><strong>MN-</strong></td>
<td>Mon</td>
<td>04/23/07</td>
<td>Osteoporosis</td>
<td>Hadley</td>
<td></td>
</tr>
<tr>
<td><strong>MN-</strong></td>
<td>Tue</td>
<td>04/24/07</td>
<td>Principles of Toxicology</td>
<td>Swanson</td>
<td></td>
</tr>
<tr>
<td><strong>MN-</strong></td>
<td>Thr</td>
<td>04/26/07</td>
<td>Common Toxins</td>
<td>Swanson</td>
<td></td>
</tr>
<tr>
<td><strong>MN-</strong></td>
<td>Fri</td>
<td>04/27/07</td>
<td>TBA</td>
<td>Staff</td>
<td></td>
</tr>
</tbody>
</table>

**EXAM 4 PHA 622 SECTION 004**
**FINAL EXAM WEEK 04/30-05/04/07**
**GRADES DUE 05/07/07**